INmune Bio, Inc. (INMB)
NASDAQ: INMB · Real-Time Price · USD
7.86
+0.57 (7.82%)
At close: May 16, 2025, 4:00 PM
7.93
+0.07 (0.89%)
After-hours: May 16, 2025, 7:58 PM EDT
INmune Bio Stock Forecast
Stock Price Forecast
According to 3 professional analysts, the 12-month price target for INmune Bio stock ranges from a low of $20 to a high of $30. The average analyst price target of $24.33 forecasts a 209.54% increase in the stock price over the next year.
Price Target: $24.33 (+209.54%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Feb 13, 2025.
Analyst Ratings
The average analyst rating for INmune Bio stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 2 | 2 | 2 | 2 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 3 | 3 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Maxim Group | Maxim Group | Strong Buy Maintains $22 → $30 | Strong Buy | Maintains | $22 → $30 | +281.68% | Feb 13, 2025 |
| Scotiabank | Scotiabank | Buy Maintains $22 → $23 | Buy | Maintains | $22 → $23 | +192.62% | Feb 11, 2025 |
| Alliance Global Partners | Alliance Global Partners | Strong Buy Initiates $20 | Strong Buy | Initiates | $20 | +154.45% | Oct 21, 2024 |
| Scotiabank | Scotiabank | Buy Initiates $22 | Buy | Initiates | $22 | +179.90% | Aug 22, 2024 |
| Baird | Baird | Buy Initiates $16 | Buy | Initiates | $16 | +103.56% | Jun 1, 2023 |
Financial Forecast
Revenue This Year
n/a
from 14.00K
Revenue Next Year
5.52M
EPS This Year
-1.83
from -2.11
EPS Next Year
-1.74
from -1.83
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | 15.2M | 25.5M | ||
| Avg | n/a | 5.5M | 15.9M | ||
| Low | n/a | n/a | 2.6M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | 362.2% | ||
| Avg | - | - | 189.0% | ||
| Low | - | - | -53.7% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.66 | -1.18 | -0.83 | ||
| Avg | -1.83 | -1.74 | -1.32 | ||
| Low | -1.94 | -2.18 | -1.62 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.